The FDA has gathered a group of medical experts together today to review and discuss Afrezza, an inhaled, rapid-acting insulin designed for the treatment of Type 1 and Type 2 diabetes. At the end of today's all-day meeting, the experts will vote on whether or not to recommend Afrezza's approval.
This is Mannkind's third attempt at getting Afrezza approved. The FDA rejected the product both times previously. For this resubmission, Mannkind conducted two phase III studies of Afrezza, one each in Type 1 and Type 2 diabetes.
TheStreet's biotech columnist Adam Feuerstein published a preview of today's panel on Monday.
Follow along all the action today as Feuerstein live blogs the Afrezza panel.